This analysis involved profiling 18,000 transcripts (whole transcriptome atlas (WTA)) and 60 key tumor-immune proteins across 245 ROIs, which included tumor-adjacent normal lung epithelium (hereafter termed para-tumor ROI), tumor cell-enriched areas (inside the tumor area and cytokeratin-positive; hereafter termed tumor nest ROI), and immune/T-cell-enriched areas (inside the tumor area and CD45+/CD3+; hereafter termed tumor stroma ROI), from the aforementioned 44 LS-SCLC tumors (Fig. 3b). This evidence concerns the gene PTPRC and small cell lung carcinoma.